- Home
- GNTA vs IKNA Comparison
GNTA vs IKNA Comparison
Compare GNTA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- IKNA
- Stock Information
- Founded
- GNTA 2014
- IKNA 2016
- Country
- GNTA Italy
- IKNA United States
- Employees
- GNTA N/A
- IKNA N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- IKNA Health Care
- Exchange
- GNTA Nasdaq
- IKNA Nasdaq
- Market Cap
- GNTA 81.2M
- IKNA 61.8M
- IPO Year
- GNTA 2021
- IKNA 2021
- Fundamental
- Price
- GNTA $3.26
- IKNA $1.34
- Analyst Decision
- GNTA Strong Buy
- IKNA Strong Buy
- Analyst Count
- GNTA 1
- IKNA 1
- Target Price
- GNTA $25.00
- IKNA $4.00
- AVG Volume (30 Days)
- GNTA 27.2K
- IKNA 71.8K
- Earning Date
- GNTA 01-01-0001
- IKNA 08-07-2025
- Dividend Yield
- GNTA N/A
- IKNA N/A
- EPS Growth
- GNTA N/A
- IKNA N/A
- EPS
- GNTA N/A
- IKNA N/A
- Revenue
- GNTA N/A
- IKNA N/A
- Revenue This Year
- GNTA N/A
- IKNA N/A
- Revenue Next Year
- GNTA N/A
- IKNA N/A
- P/E Ratio
- GNTA N/A
- IKNA N/A
- Revenue Growth
- GNTA N/A
- IKNA N/A
- 52 Week Low
- GNTA $2.74
- IKNA $0.97
- 52 Week High
- GNTA $7.28
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- GNTA 22.05
- IKNA 54.06
- Support Level
- GNTA $2.90
- IKNA $1.31
- Resistance Level
- GNTA $3.29
- IKNA $1.37
- Average True Range (ATR)
- GNTA 0.18
- IKNA 0.05
- MACD
- GNTA -0.05
- IKNA -0.01
- Stochastic Oscillator
- GNTA 9.02
- IKNA 26.85
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.